Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 189

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 189
---
 IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public offering. The chairman of our board of directors is a lender under one of the Bridge Loans. As of January 15, 2025, the Company received $250,000 under such Bridge Loans.

Between December 2023
and January 2024, we entered into loan agreements, or the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate
amount of $150,000 from the lenders thereto including certain related parties. In October 2024, we amended the 2024 Loan Agreements
pursuant to which the 2024 Loan Agreements have been extended until August 31, 2025, shall bear interest at 8% per annum until
maturity commencing as of September 1, 2024 and we agreed to pay the lenders at maturity an additional aggregate amount of $50,000
as a risk premium. Furthermore, upon the occurrence of a Qualifying IPO, the 2024 Loan Agreements lenders, shall be granted warrants
to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a
price per share equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days
following the consummation of such initial public offering.

<div align='center'>116</div>

Agreements and Arrangements With, and Compensation of, Directors and Executive Officers

Certain of our executive
officers have employment agreements with us. These agreements will terminate at the closing of this offering and will be replaced by
new employment agreements, which will contain customary provisions and representations, including confidentiality, non-competition, non-solicitation
and inventions assignment undertakings by the executive officers. None of our employment or service provider agreements contain any terms
providing for severance benefits. Under current applicable Israeli employment laws, we may not be able to enforce (either in whole or
in part) covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of
our former employees. See “Management—Compensation of Executive Officers and Directors